Cell-penetrating peptides derived from venom, synthetic design, and natural sources are emerging as superior vehicles for delivering peptide and protein drugs into cells, overcoming the cell membrane barrier that limits most biologic therapeutics.
3 CPP generationsFrom natural venom-derived peptides to synthetic cyclic, glycosylated, and D-form designs — CPPs have evolved into practical drug delivery vehicles with superior safety and efficiency
What the researchers found
The review covers three generations of CPP development:
1. Natural CPPs: Originally discovered in venoms from snakes, bees, and spiders, these peptides evolved to penetrate cell membranes as part of their toxic function but can be repurposed for drug delivery.
2. Synthetic CPPs: Modern engineering has produced several improved designs:
• Cyclic CPPs with enhanced stability and membrane penetration
• Glycosylated CPPs with improved targeting and reduced toxicity
• D-form CPPs using mirror-image amino acids for protease resistance
3. Therapeutic applications: Various CPPs have been used as vehicles to deliver peptide and protein drugs to cells in preclinical models of diverse diseases, with superior safety and efficiency compared to traditional delivery methods.
Why it matters
The biopharmaceutical industry increasingly relies on peptide and protein drugs, but their inability to cross cell membranes is a fundamental limitation. CPPs offer a solution that could unlock the therapeutic potential of biologics for intracellular targets — expanding the drug target landscape from cell-surface proteins to the entire proteome inside the cell.
How the study worked
Narrative review synthesizing literature on CPP discovery, design innovations, and therapeutic applications. Covers the evolution from natural venom-derived CPPs through synthetic engineering approaches and their preclinical applications for peptide/protein drug delivery.
What this study cannot tell us
As a review, this paper does not present new experimental data. Most CPP applications discussed are preclinical. Clinical translation challenges (immunogenicity, off-target cell penetration, manufacturing scalability) are common across the field but may not be fully addressed. The review does not systematically compare CPP performance across different cargo types or disease models. Toxicity concerns with venom-derived CPPs at therapeutic doses need careful evaluation.
How to read the evidence
This is a narrative review covering the CPP field broadly. It synthesizes findings from numerous preclinical studies but does not include systematic methodology or quality assessment. The reviewed evidence spans basic research through preclinical disease models, representing varied evidence levels.
When this study was published
Published in 2023, this review captures the current state of CPP development including the latest synthetic design innovations. The field is rapidly advancing, with clinical trials underway for several CPP-drug conjugates.
The bigger picture
Cell-penetrating peptides sit at the intersection of peptide science, drug delivery, and biopharmaceutical development. As the pharmaceutical industry shifts toward biologic drugs (peptides, proteins, antibodies, nucleic acids), the delivery challenge becomes paramount. CPPs offer a peptide-based solution to a peptide delivery problem — an elegant recursive approach. The field is maturing from academic curiosity to clinical pipeline, with several CPP-drug conjugates in clinical trials.
Questions still open
- Which CPP design features (cyclic, glycosylated, D-form) will prove most effective for clinical translation?
- Can CPPs be engineered for tissue-specific delivery rather than general cell penetration?
- What is the maximum cargo size that CPPs can effectively deliver while maintaining cell penetration efficiency?
Common questions
What are cell-penetrating peptides?
Why are D-form and cyclic CPPs better than natural ones?
Read the original research
Recent Advances of Cell-Penetrating Peptides and Their Application as Vectors for Delivery of Peptide and Protein-Based Cargo Molecules.
Pharmaceutics, 15(8)
Citation
Zhang, Huifeng; Zhang, Yanfei; Zhang, Chuang; Yu, Huan; Ma, Yinghui; Li, Zhengqiang; Shi, Nianqiu. (2023). Recent Advances of Cell-Penetrating Peptides and Their Application as Vectors for Delivery of Peptide and Protein-Based Cargo Molecules.. Pharmaceutics, 15(8). https://doi.org/10.3390/pharmaceutics15082093